ClearMed
BriefingsDrug & Biomarker IndexSaved (0)
All Endocrinology BriefingsNature Medicine
EndocrinologyReal-World Cohort3 min read

A health-system-scale, episode-resolved multimodal atlas of cancer cachexia

In this study, we repurposed longitudinal clinicogenomic data from 52,236 patients with cancer profiled by MSK-IMPACT (2010-2024) at Memorial Sloan Kettering Cancer Center to define episode-resolved trajectories of consensus-defined cachectic weight loss and linked these events to outcomes, serology and tumor genotypes.

Published in Nature MedicineObservational cohort study
3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Source

Study Cohort

52,236 patients

Routine clinicogenomic data are, therefore, a scalable resource for discovery in cancer cachexia.

What Changes?

Endocrinology · Real-World Cohort

Current Standard

Conventional endocrinology practice relies on standard-of-care monitoring and existing regimens prior to this study.

New Finding

Motivated by these observations, we developed a multivariate model to predict impending risk of cachectic weight loss in patients with lung, colorectal and prostate cancer, validated in an independent, external from Dana-Farber Cancer Institute (n = 5,785).

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    Cachectic episodes clustered near periods of disease progression and were associated with inferior outcomes in nearly all cancer types.

  2. 02Study Evidence

    Tested in a study (52,236 patients) at the real-world stage.

  3. 03Practical Meaning

    findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.

What This Means for You

Motivated by these observations, we developed a multivariate model to predict impending risk of cachectic weight loss in patients with lung, colorectal and prostate cancer, validated in an independent, external from Dana-Farber Cancer Institute (n = 5,785). Routine clinicogenomic data are, therefore, a scalable resource for discovery in cancer cachexia.

The Discovery

Cancer cachexia is a wasting syndrome with outsized impact on morbidity and mortality, yet its drivers and systemic consequences remain poorly defined. In this study, we repurposed clinicogenomic data from 52,236 patients with cancer profiled by MSK-IMPACT (2010-2024) at Memorial Sloan Kettering Cancer Center to define episode-resolved trajectories of consensus-defined cachectic weight loss and linked these events to outcomes, serology and tumor genotypes. Cachectic episodes clustered near periods of disease progression and were associated with inferior outcomes in nearly all cancer types. Across diverse malignancies, cachectic weight loss episodes exhibited a consistent serologic signature characterized by lower albumin and hemoglobin and higher levels of liver enzymes. Numerous somatic tumor genotypes, including TP53 mutation across several diseases, were also associated with more frequent onset of cachectic episodes.

How It Works, Simply

This endocrinology research focuses on enzyme. Researchers evaluated it using an observational cohort study (52,236 patients) at the real-world cohort stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    Cachectic episodes clustered near periods of disease progression and were associated with inferior outcomes in nearly all cancer types.

  2. 02Study Evidence

    Tested in a study (52,236 patients) at the real-world stage.

  3. 03Practical Meaning

    findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.

01

Biological Mechanism & Study Design

Study Design & Cohort

Observational cohort study

Observational cohort study (52,236 patients) · Real-World Cohort

Biological Pathway & Modality

Enzyme

Intervention: A health-system-scale, episode-resolved multimodal atlas of cancer cachexia

02

Experimental Findings & Endpoints

Cancer cachexia is a wasting syndrome with outsized impact on morbidity and mortality, yet its drivers and systemic consequences remain poorly defined.

In this study, we repurposed clinicogenomic data from 52,236 patients with cancer profiled by MSK-IMPACT (2010-2024) at Memorial Sloan Kettering Cancer Center to define episode-resolved trajectories of consensus-defined cachectic weight loss and linked these events to outcomes, serology and tumor genotypes. Cachectic episodes clustered near periods of disease progression and were associated with inferior outcomes in nearly all cancer types.

Across diverse malignancies, cachectic weight loss episodes exhibited a consistent serologic signature characterized by lower albumin and hemoglobin and higher levels of liver enzymes. Numerous somatic tumor genotypes, including TP53 mutation across several diseases, were also associated with more frequent onset of cachectic episodes.

03

Clinical Translation & Practice Context

Motivated by these observations, we developed a multivariate model to predict impending risk of cachectic weight loss in patients with lung, colorectal and prostate cancer, validated in an independent, external from Dana-Farber Cancer Institute (n = 5,785).

Routine clinicogenomic data are, therefore, a scalable resource for discovery in cancer cachexia.

03

The Bottom Line · Clinical Pearl

“Routine clinicogenomic data are, therefore, a scalable resource for discovery in cancer cachexia.”

Published in Nature Medicine · Current Stage: Real-World Cohort

Practical Next Step

Questions for Your Next Doctor Visit

  1. 1Based on my health history, do these endocrinology findings (patients with cancer profiled by MSK-IMPACT (2010-2024) at Memorial Sloa) apply to my situation?
  2. 2How do the potential benefits of this approach compare with the standard care I'm currently using?
  3. 3Given the study's key limitation (observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.), what risks or follow-up steps should we watch for?
Endocrinology · Real-World Cohort
Study Type
Observational cohort study

Observational cohort study (52,236 patients)

Evidence Score
3/5 · Real-World Observation
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

Who It Applies To
Patients with cancer profiled by MSK-IMPACT (2010-2024) at Memorial Sloa
Intervention & Mechanism
A health-system-scale, episode-resolved multimodal atlas of cancer cachexia

Enzyme

Key Limitation
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.

Translational Stage

LEVEL 2 · Real-World Cohort

Classified as Observational cohort study along the clinical evidence continuum

  1. Lab & Discovery
  2. Early Trials
  3. Human Evidence
  4. 4Real-World CohortActive

Indexed Clinical Entities

KRAS, EGFR & BRCA Oncogenes

Original Publication & AMA Citation

A health-system-scale, episode-resolved multimodal atlas of cancer cachexia. Nature Medicine. Published 2026;Oct 12. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/42864412/

Nature Medicine

https://pubmed.ncbi.nlm.nih.gov/42864412/

Read Original Paper

Continue Reading

Related in Endocrinology

View all Endocrinology briefings →
ENDOCRINOLOGY · CLINICAL PRACTICE

Ozempic in Pregnancy: Diabetes, Not Drug, Linked to Early Births?

The reason you're taking Ozempic or Wegovy matters during pregnancy, with underlying diabetes potentially posing a greater risk than the medication itself. This study challenges the previously held, often generalized, assumption that GLP-1 medications alone are responsible for pregnancy complications.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDaily
ENDOCRINOLOGY · REAL-WORLD COHORT

Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes

Teplizumab-specific recommendations are identified, with broader principles framed for adaptation across health systems. This article addresses who should lead care, how to approach eligibility and timing, how to assess β-cell reserve and infection risk, how to sequence treatment with diabetic ketoacidosis recovery and early education, and how to monitor treatment safely.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readDiabetes Care
ENDOCRINOLOGY · REAL-WORLD COHORT

Transient Cognitive Vulnerability After Hypoglycemia in Adults With Type 1 Diabetes: Evidence From Continuous Glucose Monitoring and Cognitive Ecologic Momentary Assessment

Hypoglycemia was associated with a transient period of cognitive vulnerability largely confined to the hour after an event, with little evidence of delayed effects. Findings support avoiding or exercising caution during cognitively demanding tasks for up to an hour after a hypoglycemic event.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readDiabetes Care